Statistics

Total Visits

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER256

Select a period of time:

Number of views in the range

Views
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER215

Views

Views
June 20250
July 202511
August 20250
September 20250
October 20253
November 20250
December 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
Brazil5
Argentina1
Ecuador1
Spain1
Ethiopia1
Saint Kitts And Nevis1
 

Top cities views

Views
Addis Ababa1
Basseterre1
Benalmádena1
Brasília1
Brusque1
Campinas1
Fort Lauderdale1
Los Angeles1
Monte Grande1
Reisterstown1